

ONCOLOGY THERAPEUTIC AREAS OF INTEREST

• *Isatuximab*

- Generate data on Isa SC OBI in NDMM, including fixed duration/length of treatment & alternating/sequential treatment approaches in combination with novel agents in Ti and Te NDMM Generate data on use of Isa SC OBI with novel agents in HR SMMNDMM and RRMM patients
- Generate data for Isa SC OBI to support optimisation of treatment of patients with MM and HCPs
 - Investigate time in clinic, HCP workflow efficiency, patient and caregiver burden, and benefits of home-based treatment
- Generate data on Isa combinations with novel modalities and targets and alternate sequencing in newly diagnosed patients or early relapse, including but not limited to:
 - Isa + BCMA (TCE, CAR-T)
 - Isa + BCMA and GPRC5D (TCE)
 - Isa + immunomodulators

If you have any further questions, please contact your Sanofi Oncology Medical Science Liaison (MSL).